Animal funds

$1.22 billion in sales expected for Elanco Animal Health Incorporated (NYSE: ELAN) this quarter

Wall Street brokers expect Elanco Animal Health Incorporated (NYSE:ELAN – Get a rating) will report sales of $1.22 billion for the current quarter, according to Zacks Investment Research. Three analysts have released earnings estimates for Elanco Animal Health, with the highest sales estimate at $1.23 billion and the lowest estimate at $1.21 billion. Elanco Animal Health reported sales of $1.24 billion in the same quarter last year, suggesting a negative 1.6% year-over-year growth rate. The company is expected to announce its next quarterly results on Friday, May 6.

On average, analysts expect Elanco Animal Health to report annual revenue of $4.78 billion in the current fiscal year, with estimates ranging from $4.77 billion to $4.79 billion. dollars. For the next fiscal year, analysts expect the company to post sales of $4.96 billion, with estimates ranging from $4.90 billion to $5.05 billion. Zacks Investment Research sales averages are an average based on a survey of research analysts who provide coverage for Elanco Animal Health.

Elanco Animal Health (NYSE: ELAN – Get a rating) last released its quarterly results on Wednesday, February 23. The company reported earnings per share of $0.21 for the quarter, beating the Zacks consensus estimate of $0.17 by $0.04. Elanco Animal Health had a positive return on equity of 6.51% and a negative net margin of 9.91%. The company posted revenue of $1.11 billion in the quarter, versus $1.10 billion expected by analysts. During the same period last year, the company posted EPS of $0.12. The company’s revenue was down 2.3% year-over-year.

(A d)

Right now, helium is one of the best investments in the world. It’s Earth’s most non-renewable resource and it’s running out fast. It’s a crisis because helium is essential in medical diagnostics, military weapons and semiconductors, which are the chips that power all 21st century gadgets, devices and vehicles.

ELAN has been the subject of several recent analyst reports. Zacks Investment Research upgraded Elanco Animal Health from a “sell” rating to a “hold” rating in a report released Monday. Morgan Stanley kicked off Elanco Animal Health coverage in a Thursday, Nov. 18, report. They set an “overweight” rating and a target price of $40.00 on the stock. Finally, Barclays raised its price target on Elanco Animal Health from $30.00 to $32.00 and gave the stock an “equal weight” rating in a report on Monday. Five analysts gave the stock a hold rating and six gave the company a buy rating. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $37.63.

NYSE MOMENTUM opened at $28.94 on Wednesday. The stock has a fifty-day moving average of $26.85 and a 200-day moving average of $30.10. Elanco Animal Health has a 52-week low of $24.15 and a 52-week high of $37.49. The company has a debt ratio of 0.82, a current ratio of 2.32 and a quick ratio of 1.30.

Several institutional investors and hedge funds have recently changed their holdings in ELAN. Bank Julius Baer & Cie AG Zurich increased its equity stake in Elanco Animal Health by 11.2% during the third quarter. Bank Julius Baer & Co. Ltd Zurich now owns 170,942 shares of the company worth $5,451,000 after buying 17,267 additional shares in the last quarter. Dendur Capital LP increased its position in Elanco Animal Health shares by 6.3% during the third quarter. Dendur Capital LP now owns 3,367,829 shares of the company valued at $107,400,000 after purchasing an additional 200,000 shares last quarter. Man Group plc increased its equity stake in Elanco Animal Health by 371.7% during the second quarter. Man Group plc now owns 293,716 shares in the company worth $10,188,000 after acquiring a further 231,454 shares in the last quarter. Truist Financial Corp increased its stake in shares of Elanco Animal Health by 5.2% during the third quarter. Truist Financial Corp now owns 304,861 shares of the company worth $9,722,000 after acquiring 15,098 additional shares in the last quarter. Finally, Senator Investment Group LP increased its stake in shares of Elanco Animal Health by 23.1% during the 3rd quarter. Senator Investment Group LP now owns 3,200,000 shares of the company worth $102,048,000 after acquiring an additional 600,000 shares in the last quarter. Institutional investors hold 97.90% of the company’s shares.

Company Profile Elanco Animal Health (Get a rating)

Elanco Animal Health, Inc is committed to the innovation, development, manufacturing and marketing of pet and consumer animal products. It offers products in the following four categories: Pet Disease Prevention, Pet Therapeutics, Protein and Health of the Future of Food Animals, and Ruminants and Swine for Food Animals. food.

See also

Get a Free Copy of Zacks’ Research Report on Elanco Animal Health (ELAN)

For more information on Zacks Investment Research’s research offerings, visit Zacks.com

Earnings history and estimates for Elanco Animal Health (NYSE:ELAN)

This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

Should you invest $1,000 in Elanco Animal Health right now?

Before you consider Elanco Animal Health, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated, top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and Elanco Animal Health didn’t make the list.

While Elanco Animal Health currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the 5 actions here